⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALLO News
Allogene Therapeutics, Inc. Common Stock
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
globenewswire.com
ALLO
Global Cell Expansion Market - Forecast 2026-2032 | Market to Reach USD 56.86 Billion as Automation, AI, and Cell and Gene Therapy Drive 15.80% CAGR
globenewswire.com
A
ALLO
BDX
BIIB
CHKP
DG
GEHC
REGN
TMO
Engineered T Cells Market - Global Forecast 2026-2032 | CAR-T, TCR-T, and Allogeneic Platforms Unlock 8.06% CAGR and a USD 41.99 Billion Opportunity
globenewswire.com
ALLO
AMGN
ATRA
AUTL
BB
BMY
CRSP
FATE
GILD
IMCR
REGN
PFE
SANG
TCRT
Global Cell & Gene Therapy Market Size and Forecast Report 2026-2036 | Market to Reach US$126.86 Billion at 17.3% CAGR as CRISPR, CAR-T and Scalable Manufacturing Drive Growth
globenewswire.com
ALLO
ATRA
BEAM
BMRN
BMY
CRSP
GILD
INTC
JNJ
NVS
VRTX
CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 2036, Fueled by Treatment Innovation and Rising Patient Demand
globenewswire.com
GILD
NVS
BMY
CRSP
BIO
ADBT
BIIB
JNJ
REGN
AMGN
CELC
ALLO
MBIO
AUTL
CAR T-cell Therapy for NHL Clinical Trial Landscape Expands: Over 70 Companies Advancing Next-Generation Therapies | DelveInsight
globenewswire.com
NVS
ALLO
LEGN
CBIO
MBIO
CRSP
INCY
IMPP
SANA
VOR
CARG
AUTL
ARCL
LYEL
PRE
BEAM
CART
TAK
AZN
MRK
BMY
GEN
DGX
GMAB
ABBV
RLGT
CRGO
JNJ
GILD
JAZZ
SYBX
CASI
ATRA
SHEN
BIIB
VREX
Form 8-K
sec.gov
ALLO
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
globenewswire.com
ALLO
Allogene Therapeutics Announces Participation in September Investor Conference
globenewswire.com
ALLO
Global CD70-Targeting Therapies Market Report 2026 - Highlights Clinical Innovation, Pipeline Trends and Commercial Opportunities
globenewswire.com
ALLO
CRSP
JNJ
PFE
ADCT
REGN
MRNA
BMY
GILD
AMGN
BIIB
AZN
NVS
LLY
ABBV